Matthew Plunkett, EVP, Corporate Development at CTI BIOPHARMA CORP (CTIC), sold 75,869 shares at $1.60 ($119K) on 2015-09-24, disclosed to the SEC on 2015-09-25.
Scheduled sale ($119k) by EVP, Corporate Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.52 | 3,600 | $5K | 4.6% |
| 2 | $1.53 | 200 | $306 | 0.3% |
| 3 | $1.53 | 13,201 | $20K | 16.9% |
| 4 | $1.53 | 6,899 | $11K | 8.9% |
| 5 | $1.54 | 100 | $154 | 0.1% |
| 6 | $1.54 | 289 |
| $445 |
| 0.4% |
| 7 | $1.55 | 800 | $1K | 1.0% |
| 8 | $1.55 | 600 | $930 | 0.8% |
| 9 | $1.56 | 800 | $1K | 1.0% |
| 10 | $1.57 | 1,700 | $3K | 2.2% |
| 11 | $1.58 | 1,000 | $2K | 1.3% |
| 12 | $1.58 | 5,330 | $8K | 7.1% |
| 13 | $1.59 | 16,400 | $26K | 21.9% |
| 14 | $1.59 | 7,000 | $11K | 9.3% |
| 15 | $1.60 | 14,400 | $23K | 19.3% |
| 16 | $1.60 | 1,500 | $2K | 2.0% |
| 17 | $1.61 | 660 | $1K | 0.9% |
| 18 | $1.61 | 1,390 | $2K | 1.9% |
| Total | $1.57 avg | 75,869 | $119K | 100% |
| Filing → |
| CTIC | SELL | 2016-01-06 | $15K | — | Filing → |
| CTIC | SELL | 2015-12-04 | $9K | — | Filing → |
| CTIC | SELL | 2015-11-06 | $14K | — | Filing → |